2015 News Releases

Keyword Search
 
2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
03/24/15StemCells, Inc. Appoints Ian Massey as President and Chief Operating Officer
NEWARK, Calif., March 24, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, today announced that Ian Massey, D. Phil., has joined its executive team as President and Chief Operating Officer, effective March 23, 2015. In this new role, Dr. Massey has direct responsibility for all aspects of the Company's research and development, manufacturing, regulatory affairs, and quality as... 
Printer Friendly Version
03/16/15StemCells, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Update
Conference Call to be Hosted March 16, 2015 at 4:30 p.m. EDT (1:30 PM PDT) NEWARK, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics for diseases of the central nervous system, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2014. "We achieved three significant clinical translation milestones in 2014: the completi... 
Printer Friendly Version
03/10/15StemCells, Inc. to Participate at the Wall Street Analyst Forum 25th Annual Institutional Investor Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., March 10, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Management will make a presentation on the Company's programs and operations at the Wall Street Analyst Forum 25th Annual Institutional Investor Conference. Management is scheduled to speak at 10:35 a.m. Eastern Daylight Time on Thursday, March 19, at The University Club located at 1 West 54th Street in NYC. ... 
Printer Friendly Version
03/09/15StemCells, Inc. Announces Webcast to Discuss Fourth Quarter and Full Year 2014 Financial Results
NEWARK, Calif., March 9, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the fourth quarter and full year ended December 31, 2014, after the market close on Monday, March 16. StemCells will host a conference call and webcast to discuss its results and an update on its business ... 
Printer Friendly Version
02/05/15Safety and Preliminary Efficacy of Human Neural Stem Cells in StemCells, Inc.'s Dry AMD Study to be Presented at Ophthalmology Conference
NEWARK, Calif., Feb. 5, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, announced today that Theodore Leng, MD, MS, Clinical Assistant Professor of Ophthalmology at the Byers Eye Institute at Stanford, Stanford University School of Medicine and a principal investigator on StemCells, Inc.'s Phase I/II study in dry age related macular degeneration will be presenting findings on... 
Printer Friendly Version
02/02/15StemCells, Inc. to Participate at the 17th Annual BIO CEO & Investor Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., Feb. 2, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Management will make a presentation on the Company's programs and operations at the 17th Annual BIO CEO & Investor Conference. Management is scheduled to speak at 8:30 a.m. EST on Monday, February 9, at the Waldorf Astoria in New York City. A live webcast of the presentations will be available through the... 
Printer Friendly Version
01/26/15StemCells, Inc. Posts Letter to Shareholders
NEWARK, Calif., Jan. 26, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, posted today the following Letter to Shareholders from its President and CEO, Martin McGlynn. January 26, 2015 Dear Fellow Shareholders: Over the past year, StemCells, Inc. has made substantial progress. We completed enrollment and dosing in our Phase I/II clinical trials in two major indicat... 
Printer Friendly Version